ArticleThe Journal of clinical investigation2008
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients.
Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Helicobacter pylori eradication for immune thrombocytopenia reduces non-response and raises platelet counts: Meta-analysis of randomized trials.Annals of hematology · 2026Pooled it
- Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review.Haematologica · 2009Pooled it
- Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance.Heart and vessels · 2014Trial
- Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals.International journal of hematology · 2012Trial
- Investigating the link betweenAnnals of medicine and surgery (2012) · 2026Article
- HELICOBACTER PYLORI BEYOND THE STOMACH: WHEN THE STORY CHANGES.Arquivos de gastroenterologia · 2026Review
- Immune Thrombocytopenia Induced by Helicobacter pylori Infection: A Case Report and Literature Review.Cureus · 2025Article
- Identification of miRNAs that target Fcγ receptor-mediated phagocytosis during macrophage activation syndrome.Frontiers in immunology · 2024Article
- Possible immune mechanisms of gut microbiota and its metabolites in the occurrence and development of immune thrombocytopenia.Frontiers in microbiology · 2024Review
- Impact ofDiagnostics (Basel, Switzerland) · 2023Review
- How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023Review
- Review
- Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia.Science China. Life sciences · 2021Article
- Review
- Extra-Gastric Manifestations ofJournal of clinical medicine · 2020Review
- Efficacy ofMicroorganisms · 2020Article
- Host-microbiota interactions in immune-mediated diseases.Nature reviews. Microbiology · 2020Review
- Helicobacter pylori is Associated with Less Fistulizing, Stricturing, and Active Colitis in Crohn's Disease Patients.Cureus · 2019Article
- Helicobacter pylori: An Underrated Cause of Immune Thrombocytopenic Purpura. A Comprehensive Review.Cureus · 2019Review
- Association between Helicobacter pylori infection and platelet count in mice.Experimental animals · 2018Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia purpura (ITP) is a bleeding disorder in which platelet-specific autoantibodies cause a loss of platelets. In a subset of patients with ITP and infected with Helicobacter pylori, the number of platelets recovers after eradication of H. pylori. To examine the role of H. pylori infection in the pathogenesis of ITP, the response of 34 ITP patients to treatment with a standard H. pylori eradication regimen, irrespective of whether they were infected with H. pylori, was evaluated. Eradication of H. pylori was achieved in all H. pylori-positive patients, and a significant increase in platelets was observed in 61% of these patients. By contrast, none of the H. pylori-negative patients showed increased platelets. At baseline, monocytes from the H. pylori-positive patients exhibited an enhanced phagocytic capacity and low levels of the inhibitory Fcgamma receptor IIB (FcgammaRIIB). One week after starting the H. pylori eradication regimen, this activated monocyte phenotype was suppressed and improvements in autoimmune and platelet kinetic parameters followed. Modulation of monocyte FcgammaR balance was also found in association with H. pylori infection in individuals who did not have ITP and in mice. Our findings strongly suggest that the recovery in platelet numbers observed in ITP patients after H. pylori eradication is mediated through a change in FcgammaR balance toward the inhibitory FcgammaRIIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.